US targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks
1. Ozempic and Wegovy face Medicare price negotiations by 2027. 2. Upcoming negotiations could impact NVO's revenue significantly.
FAQ
Why Bearish?
Price negotiations for Ozempic could reduce revenue, similar to past drug pricing impacts.
How important is it?
The article indicates potential revenue reductions for NVO due to Medicare negotiations.
Why Long Term?
Long-term revenue effects expected as Medicare negotiations take effect in 2027.